GlobeNewswire·Jun 3, 2026, 10:58 PM ET

Jade Biosciences Announces Pricing of Public Offering of Common Stock

Jade Biosciences, Inc. (NASDAQ: JBIO) priced a public offering of 10,000,000 common stock shares at $15.00 per share.
The gross proceeds from the offering are expected to be $150.0 million, excluding any exercise of the underwriters' option for additional shares.
All shares are being sold by Jade, with a closing expected on June 5, 2026, subject to customary conditions.
Underwriters have a 30-day option to purchase up to an additional 1,500,000 shares at the public offering price less underwriting discounts.
Net proceeds will fund clinical trials, preclinical studies, manufacturing, research and development, capital expenditures, working capital, and general corporate purposes.
Jefferies, TD Cowen, & UBS Investment Bank are acting as joint book-running managers, LifeSci Capital as passive book-running manager, & BTIG as lead manager.
The offering is conducted under a Form S-3 shelf registration statement declared effective on May 15, 2026.
Jade's lead candidate JADE101 targets APRIL for immunoglobulin A nephropathy, while the pipeline includes JADE201 (anti-BAFF-R) & JADE301 (undisclosed).
Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount.